Zanubrutinib is a next-generation, selective Bruton tyrosine kinase inhibitor with efficacy in relapsed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). We compared zanubrutinib with bendamustine-rituximab to determine its effectiveness as frontline therapy in patients with CLL or SLL.

Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial / Tam, Constantine S; Brown, Jennifer R; Kahl, Brad S; Ghia, Paolo; Giannopoulos, Krzysztof; Jurczak, Wojciech; Šimkovič, Martin; Shadman, Mazyar; Österborg, Anders; Laurenti, Luca; Walker, Patricia; Opat, Stephen; Chan, Henry; Ciepluch, Hanna; Greil, Richard; Tani, Monica; Trněný, Marek; Brander, Danielle M; Flinn, Ian W; Grosicki, Sebastian; Verner, Emma; Tedeschi, Alessandra; Li, Jianyong; Tian, Tian; Zhou, Lei; Marimpietri, Carol; Paik, Jason C; Cohen, Aileen; Huang, Jane; Robak, Tadeusz; Hillmen, Peter. - In: THE LANCET ONCOLOGY. - ISSN 1474-5488. - 23:8(2022), pp. 1031-1043. [10.1016/S1470-2045(22)00293-5]

Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial

Ghia, Paolo
;
2022-01-01

Abstract

Zanubrutinib is a next-generation, selective Bruton tyrosine kinase inhibitor with efficacy in relapsed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). We compared zanubrutinib with bendamustine-rituximab to determine its effectiveness as frontline therapy in patients with CLL or SLL.
2022
Antineoplastic Combined Chemotherapy Protocols
Bendamustine Hydrochloride
Humans
Piperidines
Pyrazoles
Pyrimidines
Rituximab
COVID-19
Leukemia, Lymphocytic, Chronic, B-Cell
Sequoia
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S1470204522002935-main.pdf

solo gestori archivio

Tipologia: PDF editoriale (versione pubblicata dall'editore)
Licenza: Copyright dell'editore
Dimensione 1.16 MB
Formato Adobe PDF
1.16 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/133457
Citazioni
  • ???jsp.display-item.citation.pmc??? 54
  • Scopus 171
  • ???jsp.display-item.citation.isi??? 168
social impact